Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines

Cancer Research

Volumn 58, Issue 2, 1998, Pages 263-267

  Müller, Volkmar ^a   Jensen, Elwood V ^b   Knabbe, Cornelius ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Institut fur Hormon und Fortpflanzungsforschung IHF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; STEROID; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; DRUG INTERACTIONS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 2642680837     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Beatson, G. T. On the treatment of inoperable cases in carcinoma of the mamma: suggestion for a new method of treatment with illustrative cases. Lancet, 2: 104-107, 1896.
2. Boyd, S. On oophrectomy in cancer of the breast. Br. Med. J., 2: 1161-1166, 1900.
3. Jensen, E. V., and Jacobson, H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res., 18: 384-408, 1962.
4. Toft, D., and Gorski, J. A. receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. USA, 55: 1574-1581, 1966.
5. Jensen, E. V., Block, G. E., Smith, S., Kyser, K., and DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr., 34: 55-67, 1971.
6. De Sombre, E. R., Carbone, P. P., Jensen, E. V., McGuire, W. L., Wells, S. A., Wittliff, J. L., and Lipsett, M. B. Steroid receptors in breast cancer. N. Engl. J. Med., 301: 1011-1012, 1979.
7. Reddel, R. R., and Sutherland, R. L. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumor flare. Eur. J. Cancer. Clin. Oncol., 20: 1419-1424, 1984.
8. Jordan, V. C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev., 36: 245-276, 1984.
9. Katzenellenbogen, B. S., Kendra, K. L., Norman, M. J., and Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res., 47: 4355-4360, 1987.
10. Sonnenschein, C., Papendorp, J. T., and Soto, A. M. Estrogenic effect of tamoxifen and its derivatives on the proliferation of MCF 7 breast tumor cells. Cancer Res., 44: 2790-2793, 1985.
11. Buchanan, R. B., Blamey, R. W., Durrent, K. R., Howell, A., Paterson, A. G., Preece, P. E., Smith, D. C., Williams, C. J., and Wilson, R. G. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J. Clin. Oncol., 4: 1326-1334, 1986.
12. Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N. Engl. J. Med., 319: 1681-1690, 1988.
13. Horwitz, K. B. How do breast cancers become hormone resistant? J. Steroid Biochem. Mol. Biol., 49: 295-302, 1994.
14. Wakeling, A. E., and Bowler, J. Novel antioestrogens without partial agonist activity. J. Steroid Biochem., 31: 645-653, 1988.
15. Wakeling, A. E. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat., 25: 1-9, 1993.
16. Wakeling, A. E., Dukes, M., and Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
17. Reese, J. C., and Katzenellenbogen, B. S. Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res., 19: 6595-6602, 1991.
18. Gronemeyer, H., Benhamou, B., Berry, M., Boquel, M. T., Gofflo, D., Garcia, T., Leroune, T., Metzger, D., Meyer, M. E., Tora, L., Vergezac, A., and Chambon, P. Mechanisms of antihormone action. J. Steroid Biochem. Mol. Biol., 41: 217-228, 1992.
19. McDonnell, D. P., Clemm, D. L., Hermann, T., Goldman, M. E., and Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol., 9: 659-669, 1995.
20. DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F., Saunders, C., Baum, M., Walton, P., Sutcliffe, F., and Wakeling, A. W. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54: 408-414, 1994.
21. Howell, A., DeFriend, D., Robertson, J., Anderson, L., Anderson, E., Sutcliffe, F., and Walton, P. Pharmacokinetics, pharmacological and anti-tumour effects on the specific anti-estrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer, 74: 300-308, 1996.
22. Brünner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. W., Lippman, M. E., and Clarke, R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182780. Cancer Res., 53: 3292-3232, 1993.
23. Coopman, P., Garcia, M., Brünner, N., Derocq, D., Clarke, R., and Rochefort, H. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells. Int. J. Cancer, 56: 295-300, 1994.
24. Van de Velde, P., Nique, F., Bouchoux, J., Brémaud, J., Hameau, M. C., Lucas, D., Moratille, C., Viet, S., Philibert, D., and Teutsch, G. RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J. Steroid Biochem. Mol. Biol., 48: 187-196, 1994.
25. Love, R. R., Newcomb, P. A., and Weibe, D. A. Effects of tamoxifen on serum lipoprotein levels in postmenopausal patients with node-negative breast cancer. J. Natl. Cancer Inst., 82: 1327-1332, 1990.
26. Mc Donald, C. C., and Steward, H. J. Fatal myocardial infarction in the Scottish Adjuvant Tamoxifen Trial. Br. Med. J., 303: 435-437, 1991.
27. Jordan, V. C., Phelps, E., and Lindgren, U. J. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat., 10: 31-35, 1987.
28. Jordan, V. C., Collins, M. M., Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol., 75: 305-316, 1977.
29. Knabbe, C., Lippman, M. E., Wakefield, L., Flanders, K., Kasid, A., Derynck, R., and Dickson, R. B. Evidence that transforming growth factor β is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48: 417-428, 1987.
30. Sporn, M. B., and Roberts, A. B. Peptide growth factors are multifunctional. Nature (Lond.), 332: 217-219, 1989.
31. Knabbe, C., Kopp, A., Hilgers, W., Lang, D., Müller, V., Zugmaier, G., and Jonat, W. Regulation and role of TGFβ production in breast cancer. Ann. NY Acad. Sci., 784: 263-275, 1996.
32. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Phenol red in tissue culture medium is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA, 83: 2496-2500, 1986.
33. Kopp, A., Jonat, W., Schmahl, M., and Knabbe, C. Transforming growth factor β2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res., 55: 4512-4515, 1995.
34. Gibson, M. K., Nemmers, L. A., Beckman, W. C., Davis, V. L., Curtis, S. W., and Korach, K. S. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology, 129: 2000-2010, 1991.
35. Dauvois, S., Danelian, P. S., White, R., and Parker, M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. USA, 89: 4037-4041, 1992.
36. Wakeling, A. E. Comparative studies on the effects of steroidal and nonsteroidal oestrogen antagonists on the proliferation of human breast cancer cells. J. Steroid Biochem., 34: 183-188, 1989.
37. McClelland, R. A., Manning, D. L., Gee, J. M., Anderson, E., Clarke, R., Howell, A., Dowsett, M., Robertson, J. F., Blamey, R. W., Wakeling, A. E., and Nicholson, R. I. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res. Treat., 41: 31-41, 1996.
38. Wakefield, L. M., Coletta, A. A., McCune, B. K., and Sporn, M. B. Roles for transforming growth factors-beta in the genesis, prevention and treatment of breast cancer. Cancer Treat. Res., 61: 97-136, 1992.
39. Read, L. D., Snider, C. E., Miller, J. S., Greene, G. L., and Katzenellenbogen, B. S. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol. Endocrinol., 2: 263-271, 1988.
40. Kuiper, G. G. J. M., Carlson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., and Gustafsson, J-Å. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138: 863-870, 1997.